Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from the Mexican Oncology Study Group.

被引：0

作者：

Torrecillas, L ^{[1
]}

Soto, C ^{[1
]}

Cervantes, G ^{[1
]}

Benitez, H ^{[1
]}

Acosta, A ^{[1
]}

Cortes, P ^{[1
]}

Gonzalez, F ^{[1
]}

Zamora, R ^{[1
]}

Rodriguez, G ^{[1
]}

Silva, A ^{[1
]}

Leoner, C ^{[1
]}

Sauza, F ^{[1
]}

Suarez, T ^{[1
]}

Tokunaga, J ^{[1
]}

Erazo, A ^{[1
]}

Talavera, J ^{[1
]}

机构：

[1] IMSS, Mexico City, DF, Mexico

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2004年 / 88卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S200 / S200

页数：1

共 50 条

[21] Prospective Study of Vinorelbine and Capecitabine Combination Therapy in Chinese Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
Fan, Ying
Xu, Binghe
Yuan, Peng
Wang, Jiayu
Ma, Fei
Li, Qing
Zhang, Pin
Li, Qiao
Cai, Ruigang
CHEMOTHERAPY, 2010, 56 (04) : 340 - 347
[22] A phase 2 study of oxaliplatin (O) - capecitabine (C) chemotherapy in metastatic breast cancer (MBC) patients pretreated with anthracyclines and taxanes.
Gebbia, N
Fulfaro, F
Badalamenti, G
Arcara, C
Cicero, G
Rinaldi, G
Vizzini, L
Spinnato, F
Russo, A
Valerio, MR
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 53S - 53S
[23] Capecitabine and trastuzumab: a phase II study in HER2-overexpressing metastatic breast cancer (MBC) patients pretreated with anthracyclines and/or taxanes
Schaller, G
Bangemann, N
Gonsch, T
Weber, J
Kleine-Tebbe, A
Conrad, B
Klare, P
Hindenburg, HJ
Ruhmland, B
Lakner, V
Hinke, A
BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S94 - S95
[24] A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results
Besse-Hammer, T.
Villanueva, C.
Campone, M.
Machiels, J.
Awada, A.
Magherini, E.
Dubin, F.
Semiond, D.
Pivot, X. B.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[25] Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC).
Beslija, S.
Obralic, N.
Basic, H.
Tatarevic, A.
Naila, M.
Banjin, M.
Cardzic, A.
Sosevic, A.
Pasic, A.
Ceric, T.
Salkic, B.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 20S - 20S
[26] Real world study on the efficacy and tolerability of ixabepilone monotherapy vs. combination therapy with capecitabine in metastatic breast cancer patients (MBC)
Hyder, Tara
Rosenzweig, Margaret
Brufsky, Adam M.
CANCER RESEARCH, 2021, 81 (04)
[27] Gemcitabine plus docetaxel versus capecitabine plus docetaxel for patients with anthracycline-pretreated metastatic breast cancer: a review of the results of a European Phase III trial
Chan, S
EJC SUPPLEMENTS, 2005, 3 (05): : 17 - 21
[28] A dose escalating study of cabazitaxel (XRP6258) in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy
Villanueva, C.
Awada, A.
Campone, M.
Machiels, J. P.
Besse, T.
Magherini, E.
Dubin, F.
Semiond, D.
Pivot, X.
EJC SUPPLEMENTS, 2009, 7 (02): : 268 - 268
[29] Capecitabine (X) combined with trastuzumab (H) as first-line therapy in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC)
Xu, Ligong
Song, Santai
Zhu, Jianxin
Luo, Rongcheng
Li, Lejing
Jiao, Shunchang
Pan, Hongming
Tao, Ming
Su, Yongqian
Liu, Duanqi
ANNALS OF ONCOLOGY, 2004, 15 : 38 - 38
[30] Capecitabine (X) plus vinorelbine (N) as second-line therapy in Chinese patients (pts) with metastatic breast cancer (MBC).
Xu, B
Tian, L
Wu, Q
Zhou, M
Wang, H
Tong, Z
Li, H
Li, L
Hu, G
Shi, J
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 73S - 73S

← 1 2 3 4 5 →